Arcus Biosciences (RCUS) EBIT Margin (2017 - 2026)

Arcus Biosciences' EBIT Margin history runs 10 years deep, the most recent figure standing at 788.24% for Q1 2026.

• In Q1 2026, EBIT Margin fell 35252.0% year-over-year to 788.24%; the TTM figure through Mar 2026 stood at 168.64% (up 14058.0% YoY), while the FY2025 annual figure was 156.28%, down 2837.0% from the prior year.
• EBIT Margin was 788.24% for Q1 2026 at Arcus Biosciences, down from 345.45% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 5.0% in Q2 2025 to a low of 788.24% in Q1 2026.
• Historically, EBIT Margin has averaged 329.77% across 5 years, with a median of 286.21% in 2023.
• The sharpest annual moves came in 2022 and 2023: EBIT Margin soared 61375 bps in 2022, then sank 43235 bps in 2023.
• A 5-year view of EBIT Margin shows it stood at 217.65% in 2022, then slumped by 199 bps to 650.0% in 2023, then surged by 39 bps to 396.15% in 2024, then advanced by 13 bps to 345.45% in 2025, then tumbled by 128 bps to 788.24% in 2026.
• The last three EBIT Margin figures came in at 788.24% (Q1 2026), 345.45% (Q4 2025), and 546.15% (Q3 2025), per Business Quant data.